Skip to main content

Table 1 Baseline characteristics

From: Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

  Total (n = 62)
Age (years) 59 (27–81)
Sex
 Male 45 (72.6%)
 Female 17 (27.4%)
Race
 Asian 62
ECOG performance status
 0 9 (14.5%)
 1 53 (85.5%)
Primary tumor site
 Cardia 6 (9.7%)
 Body 31 (50.0%)
 Antrum 25 (40.3%)
Tumor grade
 Well-differentiated adeno 3 (4.8%)
 Moderately differentiated 17 (27.4%)
 Poorly differentiated 22 (35.5%)
 Signet ring cell type 20 (32.3%)
Disease status
 Recurrent after surgery 5 (8.1%)
 Metastatic at diagnosis 57 (91.9%)
Number of metastatic sites
 1 organ 16 (25.8%)
 ≥ 2 organs 46 (74.2%)
HER2 positivity 10 (16.1%)
EBV positivity 3 (4.8%)
MSS 62 (100.0%)